Optoacoustic ultrasound can noninvasively provide valuable information on tumor behavior and better inform providers of whether a mass is benign or malignant. 

The American Society of Echocardiography released a new guideline document on the comprehensive use of echocardiography in the diagnosis and therapeutic intervention of rheumatic heart disease.

“These results suggest that habitual checking of social media in early adolescence may be longitudinally associated with changes in neural sensitivity to anticipation of social rewards and punishments, which could have implications for psychological adjustment,” experts of a new study recently suggested.

To address radiation concerns by interventionalists and to help speed workflows in cath labs, Shimadzu released new AI features and single button push features for table and C-arm movement. 

A new study in the Journal of Nuclear Medicine offers insight into how the condition affects the general population, as well as how radiologists can help in the cardiac amyloidosis diagnostic journey.

The FDA is reclassifying interventional cardiovascular implant simulation software into the class II (special controls) regulatory category, which will make it easier for the technology to pass regulatory approval. 

The FDA has cleared Polarean Imaging’s xenon gas-based MRI contrast agent for evaluating pulmonary function in patients aged 12 years and up.

A new clinical trial in Australia is one of the largest in the world to use brain imaging to test the impact of psychedelics on neural activity.